<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Pentaerythritol triacrylate is used in the production of ultraviolet-curable inks and coatings, electron beam irradiation- curable coatings, and radiation-cured and photocurable coatings of <z:chebi fb="5" ids="17967">urethanes</z:chebi> and <z:chebi fb="48" ids="30721">epoxy</z:chebi> resins; as a component of photopolymer and flexographic printing inks and plates and photoresists; as an ingredient of acrylic glues, adhesives, and anaerobic sealants; and as a modifier for polyester and fiberglass </plain></SENT>
<SENT sid="1" pm="."><plain>It is also used in colloidal dispersions for industrial baked coatings, waterborne and solvent-based alkyds, vinyl/acrylic nonwoven binders, paper and wood impregnates, wire and cable extrusion, polymer-impregnated concrete, and polymer concrete structural composites </plain></SENT>
<SENT sid="2" pm="."><plain>Pentaerythritol triacrylate was nominated by the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute for testing based on its high production volume and use, its potential for human exposure, and a lack of adequate testing of the chemical </plain></SENT>
<SENT sid="3" pm="."><plain>Male and female F344/N rats and B6C3F(1) mice were administered technical grade pentaerythritol triacrylate (it is reactive and therefore not available as pure pentaerythritol triacrylate) in <z:chebi fb="15" ids="15347">acetone</z:chebi> dermally for 2 weeks or 3 months </plain></SENT>
<SENT sid="4" pm="."><plain>Male and female Tg.AC hemizygous mice were administered technical grade pentaerythritol <z:chebi fb="1" ids="37080">acrylate</z:chebi> in <z:chebi fb="15" ids="15347">acetone</z:chebi> for 6 months </plain></SENT>
<SENT sid="5" pm="."><plain>Genetic toxicology was evaluated in Salmonella typhimurium and in B6C3F(1) and Tg.AC hemizygous mouse peripheral blood erythrocytes </plain></SENT>
<SENT sid="6" pm="."><plain>2-WEEK STUDY IN RATS: Groups of five male and five female F344/N rats were administered 0, 12.5, 25, 50, 100, or 200 mg pentaerythritol triacrylate/kg body weight in <z:chebi fb="15" ids="15347">acetone</z:chebi> 5 days per week for 17 days </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> rats survived to the end of the study; mean body weights of males administered 50 mg/kg or greater and 200 mg/kg females were significantly less than those of the vehicle controls </plain></SENT>
<SENT sid="8" pm="."><plain>Irritation at the site of application occurred in <z:hpo ids='HP_0000001'>all</z:hpo> dosed groups except 12.5 mg/kg females </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0001222'>Epidermal hyperplasia</z:mp>, <z:hpo ids='HP_0000962'>hyperkeratosis</z:hpo>, <z:mp ids='MP_0009794'>sebaceous gland hyperplasia</z:mp>, <z:mpath ids='MPATH_579'>ulcer</z:mpath>, epidermal degeneration, <z:hpo ids='HP_0001036'>parakeratosis</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:mp ids='MP_0001845'>inflammation</z:mp>, and suppurative <z:mp ids='MP_0001845'>inflammation</z:mp> occurred at the site of application in most dosed groups of rats </plain></SENT>
<SENT sid="10" pm="."><plain>2-WEEK STUDY IN B6C3F(1) MICE: Groups of five male and five female B6C3F(1) mice were administered 0, 12.5, 25, 50, 100, or 200 mg pentaerythritol triacrylate/kg body weight in <z:chebi fb="15" ids="15347">acetone</z:chebi> 5 days per week for 17 days </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> mice survived to the end of the study </plain></SENT>
<SENT sid="12" pm="."><plain>The final mean body weight and body <z:mp ids='MP_0005456'>weight gain</z:mp> of 25 mg/kg males were significantly greater than those of the vehicle controls, as was the mean body <z:mp ids='MP_0005456'>weight gain</z:mp> of 50 mg/kg males </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> dosed groups had irritation at the site of application </plain></SENT>
<SENT sid="14" pm="."><plain>Thymus weights of males administered 50 mg/kg or greater and 200 mg/kg females were significantly less than those of the vehicle controls </plain></SENT>
<SENT sid="15" pm="."><plain>Most dosed groups of mice had <z:mp ids='MP_0001222'>epidermal hyperplasia</z:mp>, <z:hpo ids='HP_0000962'>hyperkeratosis</z:hpo>, <z:mp ids='MP_0009794'>sebaceous gland hyperplasia</z:mp>, <z:mpath ids='MPATH_579'>ulcer</z:mpath>, epidermal degeneration, <z:hpo ids='HP_0001036'>parakeratosis</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:mp ids='MP_0001845'>inflammation</z:mp>, and suppurative <z:mp ids='MP_0001845'>inflammation</z:mp> at the site of application </plain></SENT>
<SENT sid="16" pm="."><plain>3-MONTH STUDY IN RATS: Groups of 10 male and 10 female F344/N rats were administered 0, 0.75, 1.5, 3, 6, or 12 mg pentaerythritol triacrylate/kg body weight in <z:chebi fb="15" ids="15347">acetone</z:chebi> 5 days per week for 14 weeks </plain></SENT>
<SENT sid="17" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> rats survived to the end of the study </plain></SENT>
<SENT sid="18" pm="."><plain>Mean body weights of 12 mg/kg males were significantly less than those of the vehicle controls </plain></SENT>
<SENT sid="19" pm="."><plain>Irritation at the site of application occurred in 12 mg/kg rats </plain></SENT>
<SENT sid="20" pm="."><plain>Thymus weights of males administered 3 mg/kg or greater were significantly less than those of the vehicle controls </plain></SENT>
<SENT sid="21" pm="."><plain>Hematology results indicated that pentaerythritol triacrylate induced a neutrophil count increase that would be consistent with an <z:mp ids='MP_0001845'>inflammatory response</z:mp> related to the <z:hpo ids='HP_0000964'>dermatitis</z:hpo> observed histopathologically </plain></SENT>
<SENT sid="22" pm="."><plain><z:mp ids='MP_0001222'>Epidermal hyperplasia</z:mp>, <z:hpo ids='HP_0000962'>hyperkeratosis</z:hpo>, epidermal degeneration and <z:mp ids='MP_0001651'>necrosis</z:mp>, <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:mp ids='MP_0009794'>sebaceous gland hyperplasia</z:mp> generally occurred at the application site in male and female groups administered 1.5 mg/kg or greater </plain></SENT>
<SENT sid="23" pm="."><plain>3-MONTH STUDY IN B6C3F(1) MICE: Groups of 10 male and 10 female B6C3F(1) mice were administered 0, 0.75, 1.5, 3, 6, or 12 mg pentaerythritol triacrylate/kg body weight in <z:chebi fb="15" ids="15347">acetone</z:chebi> 5 days per week for 14 weeks </plain></SENT>
<SENT sid="24" pm="."><plain>One female vehicle control mouse was sacrificed during the first week of the study due to <z:hpo ids='HP_0001251'>ataxia</z:hpo> and one 1.5 mg/kg female died during week 8 </plain></SENT>
<SENT sid="25" pm="."><plain>Mean body weights of dosed groups were similar to those of the vehicle control groups </plain></SENT>
<SENT sid="26" pm="."><plain>Irritation at the site of application occurred in the 6 and 12 mg/kg male groups </plain></SENT>
<SENT sid="27" pm="."><plain>Hematology results indicated an <z:mp ids='MP_0000219'>increased neutrophil count</z:mp> consistent with an <z:mp ids='MP_0001845'>inflammatory response</z:mp> related to the <z:hpo ids='HP_0000964'>dermatitis</z:hpo> observed histopathologically </plain></SENT>
<SENT sid="28" pm="."><plain>There also was a minimal decrease in the erythron (hematocrit, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> concentration, and erythrocyte count) likely secondary to the inflammatory skin process </plain></SENT>
<SENT sid="29" pm="."><plain>Males and females administered 1.5 mg/kg or greater generally had increased incidences of <z:mp ids='MP_0001222'>epidermal hyperplasia</z:mp>, degeneration, and <z:mp ids='MP_0001651'>necrosis</z:mp>; dermal <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:mp ids='MP_0009794'>sebaceous gland hyperplasia</z:mp>, and <z:hpo ids='HP_0000962'>hyperkeratosis</z:hpo> at the site of application </plain></SENT>
<SENT sid="30" pm="."><plain>6-MONTH STUDY IN Tg.AC HEMIZYGOUS MICE: Groups of 15 male and 15 female Tg.AC hemizygous mice were administered 0, 0.75, 1.5, 3, 6, or 12 mg pentaerythritol triacrylate per kg body weight in <z:chebi fb="15" ids="15347">acetone</z:chebi> 5 days per week for 27 weeks </plain></SENT>
<SENT sid="31" pm="."><plain>Additional groups of 15 male and 15 female mice maintained as positive controls received dermal applications of 1.25 mug 12-O-tetradecanoylphorbol-13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> per 100 mL <z:chebi fb="15" ids="15347">acetone</z:chebi> 3 days per week for 28 weeks </plain></SENT>
<SENT sid="32" pm="."><plain>Survival of <z:hpo ids='HP_0000001'>all</z:hpo> dosed groups of mice was similar to that of the vehicle controls </plain></SENT>
<SENT sid="33" pm="."><plain>With the exception of the 3 mg/kg group, body weights of male mice were less than those of the vehicle controls during the last 3 to 6 weeks of the study </plain></SENT>
<SENT sid="34" pm="."><plain>Females administered 3 mg/kg had generally <z:mp ids='MP_0001262'>reduced body weights</z:mp> during the last month of the study </plain></SENT>
<SENT sid="35" pm="."><plain>Treatment-related clinical findings included <z:mpath ids='MPATH_445'>papillomas</z:mpath> at the site of application in males and females receiving 3 mg/kg or more; <z:mpath ids='MPATH_445'>papillomas</z:mpath> were also observed in one 1.5 mg/kg male </plain></SENT>
<SENT sid="36" pm="."><plain>Heart and liver weights of 12 mg/kg males were significantly greater than those of the vehicle controls </plain></SENT>
<SENT sid="37" pm="."><plain>Lung weights of 6 and 12 mg/kg males and females were significantly decreased, as were thymus weights of 6 and 12 mg/kg females </plain></SENT>
<SENT sid="38" pm="."><plain>Squamous cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> at the site of application were associated with dermal application of pentaerythritol triacrylate </plain></SENT>
<SENT sid="39" pm="."><plain>At 6 months, <z:hpo ids='HP_0000001'>all</z:hpo> 3 and 6 mg/kg males had <z:mpath ids='MPATH_448'>squamous cell papilloma</z:mpath> at the site of application, and the incidences of this <z:hpo ids='HP_0002664'>neoplasm</z:hpo> were significantly increased in males and females receiving 3 mg/kg or more </plain></SENT>
<SENT sid="40" pm="."><plain><z:hpo ids='HP_0002860'>Squamous cell carcinomas</z:hpo> at the site of application occurred in two 3 mg/kg males, three 12 mg/kg males, and one 12 mg/kg female </plain></SENT>
<SENT sid="41" pm="."><plain>Nonneoplastic lesions noted at the site of application in dosed mice included <z:hpo ids='HP_0000962'>hyperkeratosis</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:mp ids='MP_0001222'>epidermal hyperplasia</z:mp> </plain></SENT>
<SENT sid="42" pm="."><plain>Incidences of hematopoietic cell proliferation were increased in various organs, including the liver of 12 mg/kg females, the spleen of 6 and 12 mg/kg males and females, and the mandibular lymph node of 12 mg/kg females </plain></SENT>
<SENT sid="43" pm="."><plain>A hematopoietic disorder (<z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>) occurred in 12 mg/kg males </plain></SENT>
<SENT sid="44" pm="."><plain>GENETIC TOXICOLOGY: Pentaerythritol triacrylate was not mutagenic in several strains of S. typhimurium, with or without hamster or rat liver S9 activation enzymes </plain></SENT>
<SENT sid="45" pm="."><plain>No increase in the frequency of micronucleated erythrocytes was observed in peripheral blood samples from B6C3F(1) mice treated with pentaerythritol triacrylate by skin painting for 3 months </plain></SENT>
<SENT sid="46" pm="."><plain>In contrast, similar treatment of female Tg.AC hemizygous mice for 6 months induced a significant increase in micronucleated erythrocytes; the increase in micronuclei seen in male Tg.AC hemizygous mice was judged to be equivocal </plain></SENT>
<SENT sid="47" pm="."><plain>CONTACT HYPERSENSITIVITY STUDIES: Studies were conducted with female BALB/c mice to evaluate the potential for pentaerythritol triacrylate to induce contact hypersensitization </plain></SENT>
<SENT sid="48" pm="."><plain>In an irritancy study in which formulations of pentaerythritol triacrylate (approximately 10% or 45% pure) in <z:chebi fb="15" ids="15347">acetone</z:chebi> were applied to the ear, the maximal nonirritating concentration was 0.1% and the minimal irritating concentration was 0.25% for both mixtures </plain></SENT>
<SENT sid="49" pm="."><plain>A mouse ear swelling test yielded negative results for pentaerythritol triacrylate as a potential contact sensitizer using the 10% mixture and positive results with the 45% mixture </plain></SENT>
<SENT sid="50" pm="."><plain>Positive responses were seen in local lymph node assays at concentrations of 0.05%, 0.1%, and 0.25% pentaerythritol triacrylate when the approximately 10% pentaerythritol triacrylate mixture was used and at a concentration of 0.25% pentaerythritol triacrylate when the approximately 45% pentaerythritol triacrylate mixture was used </plain></SENT>
<SENT sid="51" pm="."><plain>CONCLUSIONS: Male and female Tg.AC hemizygous mice dosed with pentaerythritol triacrylate for 6 months had significantly increased incidences of <z:mpath ids='MPATH_448'>squamous cell papillomas</z:mpath> of the skin at the site of dermal application </plain></SENT>
<SENT sid="52" pm="."><plain>Treatment-related <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo> occurred at the site of application in male mice </plain></SENT>
<SENT sid="53" pm="."><plain>Nonneoplastic lesions noted at the site of application included <z:hpo ids='HP_0000962'>hyperkeratosis</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:mp ids='MP_0001222'>epidermal hyperplasia</z:mp> </plain></SENT>
<SENT sid="54" pm="."><plain>A hematopoietic disorder (<z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>) occurred in dosed male mice </plain></SENT>
</text></document>